Elite Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Record Q3 and nine-month results with revenue and profit more than doubling year-over-year, driven by strong market share in key generics and new product launches. Outlook remains positive with further launches and R&D investment planned.
-
Q2 FY2026 revenue nearly doubled year-over-year, driven by strong lisdexamfetamine sales and expanding market share in key products. Margins declined due to competition and one-time costs, but cash flow and balance sheet strength improved. M&A remains a strategic focus.
-
Record quarterly revenue and profit growth driven by Lisdex and Elite label products, with strong cash flow and working capital. Margins are expected to decline as competition intensifies, but market share and product pipeline remain robust.
Fiscal Year 2025
-
Fiscal 2025 saw 52% revenue growth to $84 million and an 82% rise in operating income, driven by strong launches and expanding market share in key generics. The company is prioritizing M&A, maintaining low debt, and advancing a robust product pipeline.
-
Q3 revenue declined 8% year-over-year due to shipment delays, but nine-month revenue rose 35% and January saw record shipments. Major launches, including generic Vyvanse, position the company for a record year with over $70M in revenue expected.
-
Record revenue and profit growth continued, with $18.9M in quarterly revenue and $7.3M year-to-date profit. Strong cash flow and working capital support a robust pipeline, with multiple product launches and facility expansion positioning for further growth.
-
Q1 FY2025 revenue surged 109% year-over-year to $18.8M, with operating income up 141%. Multiple new product launches and facility expansion are set to drive further growth, while strong cash flow and working capital support ongoing investments.
Fiscal Year 2024
-
Record revenue and profit growth driven by direct sales under the Elite label, with a strong pipeline and new facility expansion supporting a projected minimum of $70 million in revenue for fiscal 2025. Four new ANDAs and robust R&D position the company for continued growth.